Tumor markers and lung cancer: guidelines in a cost-limited medical organization.

Abstract

The aim of our study was to evaluate the cost of the tumor marker assays most widely used in pneumological practice and the effectiveness of the percentage of DRG-based reimbursements absorbed by these assays. For this purpose we assessed the cost of lung tumor marker assays in Emilia Romagna compared to the DRG-based reimbursement of inpatients affected by… (More)

Topics

  • Presentations referencing similar topics